Publication: Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study.
Loading...
Identifiers
Date
2019-10-03
Authors
Perez de Isla, Leopoldo
Arroyo-Olivares, Raquel
Muñiz-Grijalvo, Ovidio
Diaz-Diaz, Jose Luis
Zambon, Daniel
Fuentes, Francisco
Sanchez Muñoz-Torrero, Juan F
Mediavilla, Juan Diego
Gonzalez-Estrada, Aurora
Miramontes-Gonzalez, Jose Pablo
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Inc.
Abstract
Maximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Little is known about the use of different statin regimens in FH. The objectives of the study were to describe the treatment changes and low-density lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events (ACVEs) and changes in the cardiovascular risk. SAFEHEART is a prospective follow-up nationwide cohort study in a molecularly defined FH population. The patients were contacted on a yearly basis to obtain relevant changes in life habits, medication, and ACVEs. A total of 1939 patients were analyzed. Median follow-up was 6.6 years (5-10). The estimated 10-year risk according the SAFEHEART risk equation was 1.61 (0.67-3.39) and 1.22 (0.54-2.93) at enrollment for ATV and RV, respectively (P ATV and RV are 2 high-potency statins widely used in FH. Although the reduction in LDL-C levels was greater with RV than with ATV, the superiority of RV for reducing ACVEs was not demonstrated.
Description
MeSH Terms
Adult
Aged
Atorvastatin
Cholesterol, LDL
Cohort Studies
Drug Therapy, Combination
Ezetimibe
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
Male
Middle Aged
Prospective Studies
Rosuvastatin Calcium
Treatment Outcome
Aged
Atorvastatin
Cholesterol, LDL
Cohort Studies
Drug Therapy, Combination
Ezetimibe
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
Male
Middle Aged
Prospective Studies
Rosuvastatin Calcium
Treatment Outcome
DeCS Terms
Atorvastatina
Ezetimiba
Hiperlipoproteinemia Tipo II
Hidroximetilglutaril-CoA Reductasas
Rosuvastatina Cálcica
LDL-Colesterol
Ezetimiba
Hiperlipoproteinemia Tipo II
Hidroximetilglutaril-CoA Reductasas
Rosuvastatina Cálcica
LDL-Colesterol
CIE Terms
Keywords
Atorvastatin, Familial hypercholesterolemia, Long-term prognosis, Rosuvastatin
Citation
Pérez de Isla L, Arroyo-Olivares R, Muñiz-Grijalvo O, Diaz-Díaz JL, Zambón D, Fuentes F, et al. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. J Clin Lipidol. 2019 Nov-Dec;13(6):989-996.